Tocilizumab for the fifth progression of cystic childhood craniopharyngioma-a case report
Publication date
2023-10-11
Authors
de Vos-Kerkhof, Evelien
Buis, Dennis R
Lequin, Maarten H.
Bennebroek, Carlien A
Aronica, Eleonora
Hulleman, Esther
Zwaveling-Soonawala, Nitash
van Santen, Hanneke M
Schouten-van Meeteren, Antoinette Y N
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by
Abstract
We present the case of a 15-year-old girl, with a fifth cystic progression of an adamantinomatous craniopharyngioma after multiple surgeries and previous local radiotherapy. She had severe visual impairment, panhypopituitarism including diabetes insipidus, and several components of hypothalamic damage, including morbid obesity and severe fatigue. To prevent further late effects hampering her quality of survival, she was treated biweekly with intravenous tocilizumab, an anti-interleukin-6 agent, which stabilized the cyst for a prolonged time. Based on the biology of adamantinomatous craniopharyngioma, this immune-modulating treatment seems promising for the treatment of this cystic tumor in order to reduce surgery and delay or omit radiotherapy.
Keywords
adamantinomatous craniopharyngioma, case report, cyst, hypothalamus, tocilizumab, visual impairment, Endocrinology, Diabetes and Metabolism
Citation
de Vos-Kerkhof, E, Buis, D R, Lequin, M H, Bennebroek, C A, Aronica, E, Hulleman, E, Zwaveling-Soonawala, N, van Santen, H M & Schouten-van Meeteren, A Y N 2023, 'Tocilizumab for the fifth progression of cystic childhood craniopharyngioma-a case report', Frontiers in Endocrinology, vol. 14, 1225734. https://doi.org/10.3389/fendo.2023.1225734